Long-Term Outcomes and Prognostic Factors with Reductive Hepatectomy and Sequential Percutaneous Isolated Hepatic Perfusion for Multiple Bilobar Hepatocellular Carcinoma

@article{Fukumoto2013LongTermOA,
  title={Long-Term Outcomes and Prognostic Factors with Reductive Hepatectomy and Sequential Percutaneous Isolated Hepatic Perfusion for Multiple Bilobar Hepatocellular Carcinoma},
  author={Takumi Fukumoto and Masahiro Tominaga and Masahiro Kido and Atsushi Takebe and Motofumi Tanaka and Kaori Kuramitsu and Ippei Matsumoto and Tetsuo Ajiki and Yonson Ku},
  journal={Annals of Surgical Oncology},
  year={2013},
  volume={21},
  pages={971-978}
}
Sorafenib is currently recommended as first-line therapy for patients with intermediate or advanced hepatocellular carcinoma (HCC) per Barcelona Clinic Liver Cancer staging. However, the median overall survival (OS) with sorafenib in these patients is 10.7 months with an overall response rate of 2 %. We retrospectively investigated the long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion (PIHP) for refractory intermediate or… CONTINUE READING